来自澳大利亚海洋海绵Aaptos lobata的新阿帕坦胺类似物作为线粒体调节器
Emmanuel A Makinde1, Linlin Ma1,2, George D Mellick1,2
1Institute for Biomedicine and Glycomics, Griffith University, Brisbane, QLD 4111, Australia.
Journal of natural products
|June 10, 2025
概括
海洋海绵化合物通过保护线粒体显示出治疗神经退行性疾病的前景. 这些来自Aaptos lobata的强效线粒保护性化物可能会导致治疗帕金森病等疾病的新药开发.
科学领域:
- 海洋天然产品 化学 化学
- 神经药理学神经药理学
- 线粒体生物学 线粒体生物学
背景情况:
- 线粒体功能障碍是神经退行性疾病的关键因素,包括帕金森病.
- 线粒保护性代谢物为这些衰弱性疾病提供了潜在的治疗策略.
- 海洋生物,如海绵,是新型生物活性化合物的丰富来源.
研究的目的:
- 从澳大利亚海洋海绵*Aaptos lobata*中分离和表征新的阿帕坦胺类类化合物.
- 在神经退行细胞模型中评估这些孤立化合物的线粒保护潜力.
主要方法:
- 综合化学调查使用光谱数据分析 (NMR,MS) 进行结构阐明.
- 分离了三种新的类化合物 (3,6'-二亚胺,阿帕坦A,8-二甲基亚胺) 和四种已知的化合物.
- 在SH-SY5Y神经母细胞瘤细胞中进行生物评估,用6-氧多巴胺 (6-OHDA) 诱导毒性.
主要成果:
- 化合物2,3,4,5和7显示出显著的线粒保护活性,减少细胞死亡.
- 这些活性化合物有效地减弱了线粒体膜脱极化.
- 细胞死亡衰减的明显EC50值在0.05μM至1.06μM之间.
- 缓解线粒体膜脱极化的明显EC50值在0.021μM到0.78μM之间.
结论:
- 这项研究确定了来自*Aaptos lobata*的强大的线粒保护性阿帕坦胺类类化合物.
- 这些化合物在神经退行性疾病中显示出针对线粒体的药物开发的治疗潜力.
- 对这些来自海洋的类化合物的进一步研究可能会为帕金森病和相关疾病提供新的治疗方法.
更多相关视频
07:32Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia
Published on: February 9, 2020
7.8K
08:03Unveiling Xenobiotic Transport and Effects in Isolated Mitochondria: Insights from Respirometric and Enzymatic Assays
Published on: March 7, 2025
524
相关概念视频
ATP Synthase: Mechanism
14.0K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
14.0K
The ADP/ATP Carrier Protein
3.2K
ADP/ATP carrier or AAC protein is the most abundant carrier protein in the inner mitochondrial membrane. It transports large quantities of ADP and ATP, equivalent to the average human body weight, every day. Among other transporters, ACC protein is one of the best-studied members of the mitochondrial carrier protein family. The ADP/ATP carrier protein comprises two transmembrane helices connected to a loop and a single alpha-helix on the matrix side. It switches between two conformational...
3.2K
Electron Transport Chain: Complex I and II
12.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.1K
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
